Finance

Lists
000538:SHE
Yunnan Baiyao Group Co Ltd
CNÂ¥55.00
-1.08%
(-0.60) 1D
Nov 4, 3:04:06 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 000538...
Open
CNÂ¥55.50
High
CNÂ¥55.85
Low
CNÂ¥54.65
Mkt. cap
99.20B
Avg. vol.
9.72M
Volume
13.66M
Dividend
4.77%
Quarterly dividend
CNÂ¥0.66
Ex-dividend date
Apr 30, 2026
P/E ratio
18.88
52-wk high
CNÂ¥58.20
52-wk low
CNÂ¥46.29
EPS
CNÂ¥2.91
Shares outstanding
1.78B
No. of employees
9K
Open
CNÂ¥55.50
High
CNÂ¥55.85
Low
CNÂ¥54.65
Mkt. cap
99.20B
Avg. vol.
9.72M
Volume
13.66M
Dividend
4.77%
Quarterly dividend
CNÂ¥0.66
Ex-dividend date
Apr 30, 2026
P/E ratio
18.88
52-wk high
CNÂ¥58.20
52-wk low
CNÂ¥46.29
EPS
CNÂ¥2.91
Shares outstanding
1.78B
No. of employees
9K
News stories
From web sources and news partners
Profile
Yunnan Baiyao Group Co., Ltd is a Chinese pharmaceutical company that develops and manufactures pharmaceutical products and the wholesale and retail of pharmaceutical products. The Government Pension Fund of Norway has excluded the company from investments since 21 December 2021, since the company "uses and sells body parts from pangolins which is a globally endangered species". As of 2024, state and individual investors hold 29% of the shares and private companies hold 35%. The three largest shareholders hold 58 per cent of the company's shares. Wikipedia
About Yunnan Baiyao Group Co Ltd
CEO-
Employees9.29K
Founded1902
Headquarters-
SectorPharmaceutical industry
Industry-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
10.53B
11.60B
10.28B
10.37B
Cost of goods sold
7.85B
8.05B
7.28B
7.53B
Cost of revenue
7.85B
8.05B
7.28B
7.53B
Research and development expenses
115.55M
76.79M
112.78M
101.01M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.37B
1.28B
1.50B
1.38B
Operating expense
2.67B
1.44B
1.64B
1.55B
Total operating expenses
10.52B
9.48B
8.92B
9.08B
Operating income
12.79M
2.12B
1.36B
1.29B
Other non operating income
135.88M
-17.44M
37.87M
-65.81M
EBT including unusual items
428.17M
2.36B
1.92B
1.29B
EBT excluding unusual items
233.79M
2.35B
1.74B
1.44B
Income tax expense
27.40M
330.30M
255.01M
168.57M
Effective tax rate
6.40%
13.99%
13.27%
13.06%
Other operating expenses
129.96M
6.54M
116.66M
-19.85M
Net income
376.37M
2.04B
1.66B
1.12B
Net profit margin
3.57%
17.56%
16.18%
10.81%
Earnings per share
0.18
1.10
0.87
0.63
Interest and investment income
107.27M
253.40M
367.65M
191.07M
Interest expense
-8.83M
-5.09M
-5.15M
-2.52M
Net interest expenses
98.43M
248.31M
362.50M
188.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
70.91M
2.18B
1.43B
1.35B
Gain or loss from assets sale
-8.17M
-
-3.05K
3.05K
Upcoming events
AI content may include mistakes. Learn more
Google apps